Loading...
01/10 00:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed picture: while there is revenue growth and strategic partnerships, the company faces significant challenges such as increased operating and net losses, reduced revenue guidance, and declining margins. The Q&A session highlights management's evasiveness on critical trial details, further raising concerns. These factors, combined with financial pressures from warrant revaluation and increased R&D expenses, suggest a negative sentiment, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
Q4 2024 Revenue $5.8 million, up from $5.3 million in Q4 2023, reflecting higher revenue for Vericel and a new contract with the U.S. Department of Defense.
Q4 2024 Gross Profit $0.9 million with a gross margin of 15.5%, up from $0.7 million and a 13.5% margin in Q4 2023.
Q4 2024 R&D Expenses $3 million, compared to $1.8 million in Q4 2023, primarily due to costs related to the EscharEx VALUE Phase 3 trial.
Q4 2024 SG&A Expenses $4 million, compared to $2.8 million in Q4 2023, mainly reflecting higher share-based compensation expenses.
Q4 2024 Operating Loss $6.1 million, compared to $3.9 million in Q4 2023.
Q4 2024 Net Loss $3.9 million or $0.36 per share, compared to $1.7 million or $0.19 per share in Q4 2023.
Q4 2024 Non-GAAP Adjusted EBITDA Loss $4.9 million, compared to $3.2 million in Q4 2023.
Full Year 2024 Revenue $20.2 million, up from $18.7 million in 2023, driven by higher revenue for Vericel and a new contract with the U.S. Department of Defense.
Full Year 2024 Gross Profit $2.6 million with a gross margin of 13%, down from $3.6 million and a 19.1% margin in 2023, mainly due to changes in revenue mix and higher fixed costs.
Full Year 2024 R&D Expenses $8.9 million, compared to $7.5 million in 2023, primarily due to costs related to EscharEx VALUE Phase 3 trial.
Full Year 2024 SG&A Expenses $13.1 million, compared to $11.6 million in 2023, mainly reflecting higher share-based compensation costs.
Full Year 2024 Operating Loss $19.4 million, compared to $15.3 million in 2023.
Full Year 2024 Net Loss $30.2 million or $3.03 per share, compared to $6.7 million or $0.75 per share in 2023, primarily due to financial expenses from the revaluation of warrants.
Full Year 2024 Non-GAAP Adjusted EBITDA Loss $40.8 million, compared to $12.3 million in 2023.
Cash Position at Year End 2024 $43.6 million, compared to $42.1 million at the end of 2023.
Funds Raised in 2024 $25 million through PIPE offering, $1.2 million from the exercise of Series A warrant, and $1.2 million grant from the European Commission.
EscharEx: EscharEx demonstrated superiority over SANTYL in clinical endpoints, with peak sales potential estimated at $725 million.
NexoBrid: NexoBrid generated annual revenue of $20.2 million in 2024, with projected revenue of $24 million in 2025.
Market Expansion for EscharEx: EscharEx is in Phase 3 trials for venous leg ulcers, with a new Medicare policy enhancing its commercial opportunity.
NexoBrid Market Expansion: NexoBrid is now available in over 90 burn centers in Europe and has seen a 42% increase in hospital orders in Q4 2024.
GMP Manufacturing Facility: Construction of a new GMP manufacturing facility is complete, expected to reach full operational capacity by late 2025.
Funding: Secured €16.5 million from the European Innovation Council to accelerate EscharEx development.
Strategic Partnerships: Collaborations with Solventum, Mölnlycke, MIMEDX, and Kerecis to enhance clinical trials and product offerings.
PIPE Financing: Raised $25 million through PIPE financing to support clinical and commercial growth.
Regulatory Issues: Upcoming changes in Medicare’s LCD policy will require full wound debridement and granulation tissue formation before covering cellular- and tissue-based products, which could impact reimbursement for EscharEx.
Competitive Pressures: EscharEx is positioned against SANTYL, the only FDA approved enzymatic debridement product in the U.S., which generates approximately $370 million annually.
Supply Chain Challenges: MediWound's growth is capped by manufacturing capabilities, with the new GMP manufacturing facility expected to reach full operational capacity by late 2025, pending regulatory approval.
Economic Factors: The company reported a significant increase in net loss due to financial expenses from the revaluation of warrants following a 75% increase in share price in 2024.
Clinical Trial Risks: The VALUE Global Phase 3 trial for EscharEx involves 216 patients across 40 sites, with the risk of variability and the need for interim analysis at 65% enrollment to ensure success.
EscharEx Peak Sales Potential: Estimated at approximately $725 million for its primary indications in the Sled ulcers and diabetic foot ulcers.
EscharEx Phase 3 Trial: VALUE Global Phase 3 trial launched to evaluate EscharEx for venous leg ulcers involving 216 patients across 40 sites in the U.S. and Europe.
Funding for EscharEx Development: Secured €16.5 million from the European Innovation Council to accelerate development for diabetic foot ulcers.
NexoBrid Revenue Growth: Achieved annual revenue of $20.2 million in 2024, with projected revenue of $24 million in 2025.
Manufacturing Facility: State-of-the-art GMP manufacturing facility expected to reach full operational capacity by late 2025.
2025 Revenue Projection: Projected revenue of $24 million for NexoBrid in 2025.
Operational Cash Position: Robust cash runway of approximately $44 million.
R&D Expenses: R&D expenses expected to continue due to ongoing clinical trials, particularly for EscharEx.
Capital Expenditure: $6.8 million allocated to capital expenditure for scaling up manufacturing.
PIPE Financing: MediWound raised $25 million through a PIPE financing round led by Mölnlycke.
Cash Position: The company ended the year with $43.6 million in cash, cash equivalents, and deposits.
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
The earnings call presented mixed signals. While strategic collaborations and funding are positive, the decline in revenue and increased operating loss are concerning. The Q&A highlighted ongoing projects and potential future benefits but also revealed some uncertainties, particularly regarding patient recruitment and manufacturing timelines. Despite some positive developments, the overall financial health and lack of immediate catalysts suggest a neutral market reaction.
The earnings call reveals several challenges: declining revenue, increased operating loss, and competitive pressures against EscharEx. Despite some positive developments, such as the new manufacturing facility and improved gross margin, these are overshadowed by financial struggles and supply chain issues. The Q&A session highlighted regulatory uncertainties and management's vague responses about future government purchases and financial projections. Without a share repurchase program or positive shareholder return plan, the overall sentiment is negative, likely leading to a stock price decline of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
